SUPRAX (Cefixime) Patent Expiration, LOE Window & CMS Spending

SUPRAX (Cefixime) by Lupin Pharmaceuticals: FDA Orange Book core substance LOE 2028-12-14, 6 AB generics, $0 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorLupin Pharmaceuticals
FDA Application & PathwayN202091 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE Date2028-12-14
Last Listed Patent or Exclusivity Date2028-12-14
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors6
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel